Inactive Instrument

Highlights Palatin Technologies, Inc. Nyse

Equities

PTN

US6960773041

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 08	Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease Clinical Data Results Presented At American Society of Cataract and Refractive Surgery 2024	CI
Feb. 28	Sector Update: Health Care Stocks Decline Late Afternoon	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease Clinical Data Results Presented At American Society of Cataract and Refractive Surgery 2024	Apr. 08	CI
Palatin Shares Skid After Dry Eye Drug Candidate Misses Part of Targets in Late-Stage Trial	Feb. 28	MT
Palatin Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease	Feb. 05	CI
Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024	Jan. 08	CI
Cosette Pharmaceuticals, Inc. acquired worldwide rights to Vyleesi from Palatin Technologies, Inc. for approximately $170 million.	Dec. 19	CI
Palatin Technologies, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Palatin Technoloes, Inc. Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients	23-10-18	CI
Palatin Technologies Gets Non-Compliance Notice From NYSE American	23-10-13	MT
Earnings Flash (PTN) PALATIN TECHNOLOGIES Posts Q4 Revenue $1.8M, vs. Street Est of $1.4M	23-09-28	MT
Palatin Technologies, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023	23-09-28	CI
Palatin Technologies, Inc. Completes Enrollment in Phase 3 Melody-1 Study of PL9643 for the Treatment of Patients with Dry Eye Disease	23-09-07	CI
Palatin Technologies, Inc. Initiates Clinical Program for Bremelanotide Co-Formulated with A Pde5i for the Treatment of Ed in Patients Non-Responsive to Pde5i Treatment	23-08-10	CI
Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study	23-08-08	CI
Palatin Technologies, UpScriptHealth Enter Into Telemedicine Partnership for Vyleesi Drug	23-08-07	MT
Palatin Technologies, Inc. Announces Direct-To-Consumer Telehealth Partnership with UpScriptHealth for Vyleesi	23-08-07	CI
Palatin Technologies, Inc. Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference	23-05-30	CI
Earnings Flash (PTN) PALATIN TECHNOLOGIES Reports Q3 Revenue $1.2M, vs. Street Est of $1.3M	23-05-16	MT
Palatin Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15	CI
Palatin Technologies, Inc. Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference	23-05-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Palatin Technologies, Inc. Nyse

Equities

PTN

US6960773041

Highlights

Filters